Moderna (MRNA) vs. Its Peers Critical Contrast

Moderna (NASDAQ: MRNA) is one of 126 public companies in the “Biological products, except diagnostic” industry, but how does it contrast to its peers? We will compare Moderna to related companies based on the strength of its risk, institutional ownership, dividends, analyst recommendations, earnings, valuation and profitability.

Earnings and Valuation

This table compares Moderna and its peers top-line revenue, earnings per share and valuation.

Gross Revenue Net Income Price/Earnings Ratio
Moderna $135.07 million -$384.73 million -2.86
Moderna Competitors $812.19 million $163.83 million 6.22

Moderna’s peers have higher revenue and earnings than Moderna. Moderna is trading at a lower price-to-earnings ratio than its peers, indicating that it is currently more affordable than other companies in its industry.


This table compares Moderna and its peers’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Moderna N/A N/A N/A
Moderna Competitors -4,353.74% -91.97% -36.62%

Analyst Recommendations

This is a summary of current ratings for Moderna and its peers, as provided by

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Moderna 0 0 9 0 3.00
Moderna Competitors 987 3091 6616 298 2.57

Moderna currently has a consensus price target of $27.56, indicating a potential upside of 94.60%. As a group, “Biological products, except diagnostic” companies have a potential upside of 48.28%. Given Moderna’s stronger consensus rating and higher possible upside, equities research analysts clearly believe Moderna is more favorable than its peers.

Insider & Institutional Ownership

44.5% of Moderna shares are held by institutional investors. Comparatively, 48.2% of shares of all “Biological products, except diagnostic” companies are held by institutional investors. 34.5% of Moderna shares are held by company insiders. Comparatively, 18.8% of shares of all “Biological products, except diagnostic” companies are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.


Moderna beats its peers on 7 of the 12 factors compared.

About Moderna

Moderna, Inc., a clinical stage biotechnology company, develops therapeutics and vaccines based on messenger RNA for the treatment of infectious diseases, immuno-oncology, rare diseases, and cardiovascular diseases. As of February 15, 2019 the company had 11 programs in clinical trials and a total of 20 development candidates in six modalities comprising prophylactic vaccines, cancer vaccines, intratumoral immuno-oncology, localized regenerative therapeutics, systemic secreted therapeutics, and systemic intracellular therapeutics. It has strategic alliances with AstraZeneca, Merck & Co., Vertex Pharmaceuticals, Biomedical Advanced Research and Development Authority, Defense Advanced Research Projects Agency, and Bill & Melinda Gates Foundation. The company was formerly known as Moderna Therapeutics, Inc. and changed its name to Moderna, Inc. in August 2018. Moderna, Inc. was founded in 2010 and is headquartered in Cambridge, Massachusetts.

Receive News & Ratings for Moderna Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Moderna and related companies with's FREE daily email newsletter.